Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (1): 27-31.

Previous Articles     Next Articles

Research Status and Prospect of Radiopharmaceuticals

LI Jianguo1, QIN Xiujun1, HU Bo2, GAO Jie1, LI Mei1, LIU Huan1, AN Quan1, JIN Hongtao3,*   

  1. 1Drug Safety Evaluation Center in China Institute for Radiation Protection; Shanxi Key Laboratory of Drug Toxicology and Drug for Radiation Injury, Division of Radiology and Environmental Medicine of China Institute for Radiation Protection, Shanxi Taiyuan 030006, China;
    2Irradiation Technology Factory,Shanxi Taiyuan 030006, China;
    3Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
  • Received:2018-12-23 Revised:2019-02-18 Online:2019-01-20 Published:2019-02-18

PDF (PC)

677

Abstract: Radiopharmaceuticals refers to radionuclides for clinical diagnosis or treatment, or labeled compounds, mainly including the radiological drugs for diagnosis and radiological drugs for treatment. With the popularity of SPECT/PET/PET-CT, the research and development of diagnostic radiotherapy drugs represented by 99mTc, 18F and 68Ga have developed rapidly in recent years. In recent years, more and more attention has been paid to the research and development of therapeutic radiotherapy drugs due to their good economic benefits and research and development potential. However, there is still a big gap between China and the United States and the European Union in terms of research and development investment in radioactive drugs and relevant policies and regulations. In this paper, the present situation of radiopharmaceutical research at home and abroad and the general situation of radiopharmaceutical development in China are discussed.

Key words: radioactive drugs, policies and regulations, development status, outlook

CLC Number: